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Abstract
Background: Cancer/testis (CT) genes are expressed only in the germ line and certain tumors and are most frequently
located on the X-chromosome (the CT-X genes). Amongst the best studied CT-X genes are those encoding several MAGE
protein families. The function of MAGE proteins is not well understood, but several have been shown to potentially
influence the tumorigenic phenotype.
Methodology/Principal Findings: We undertook a mutational analysis of coding regions of four CT-X MAGE genes, MAGEA1,
MAGEA4, MAGEC1, MAGEC2 and the ubiquitously expressed MAGEE1 in human melanoma samples. We first examined cell
lines established from tumors and matching blood samples from 27 melanoma patients. We found that melanoma cell lines
from 37% of patients contained at least one mutated MAGE gene. The frequency of mutations in the coding regions of
individual MAGE genes varied from 3.7% for MAGEA1 and MAGEA4 to 14.8% for MAGEC2. We also examined 111 fresh
melanoma samples collected from 86 patients. In this case, samples from 32% of the patients exhibited mutations in one or
more MAGE genes with the frequency of mutations in individual MAGE genes ranging from 6% in MAGEA1 to 16% in MAGEC1.
Significance: These results demonstrate for the first time that the MAGE gene family is frequently mutated in melanoma.
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Introduction
Cancer/testis (CT) genes are expressed primarily in the germ line
but are also active in a number of human tumors including those of
the lung, breast, ovary and skin [1]. Amongst the CT-genes is a
subset with very tight transcriptional regulation that is specifically
expressed in spermatogonia, completely undetectable in somatic
tissues and encoded on the X-chromosome [2]. The proteins
derived from these CT-X genes are significantly immunogenic
when aberrantly expressed in human tumors and are being widely
studied in the context of therapeutic cancer vaccines [3,4].
Currently, two phase III trials are being undertaken with a vaccine
containing the CT-X protein MAGEA3 as an adjuvant therapy for
non-small cell lung cancer and melanoma [5].
Due to their strong up regulation in tumors, it has been widely
speculated that the CT-X genes might play a role in the
tumorigenic process. This has been difficult to prove, however,
as their function remains obscure. Nevertheless a number of in vitro
studies, focused on the MAGE proteins, have found evidence that
they can interfere with p53 mediated apoptosis and promote cell
proliferation [6,7,8,9,10]. In addition, a number of studies have
found CT-X expression to be linked with both more advanced and
more aggressive tumors [11,12,13]. To complicate this scenario,
however, there have also been observations that link the
expression of individual MAGE genes with a better prognosis
and longer survival [14,15,16].
Recently, it has begun to be possible to undertake genome-wide
investigations of somatic mutations in human tumors [17,18,19].
Within the published data, we identified reports of missense
mutations in the CT-X antigen genes MAGEA1, MAGEA4,
MAGEC1, MAGEC2, as well as the genes for the ubiquitously
expressed MAGEE1 (also encoded on the X chromosome) in breast
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mutations is low, we reasoned that their mutation might not be
simply due to chance as none were observed to be mutated in
colon or pancreatic tumors although the same genes were
sequenced in similar numbers of tumors [17,19]. Furthermore,
MAGEE1 was mutated sufficiently frequently to be classified as a
candidate cancer gene (CAN-gene) in breast cancer and thus
potentially a driver of tumorigenesis [17].
Since greater knowledge of somatic MAGE mutations in human
tumors might cast further light on their potential role in
tumorigenesis, as well as provide important information relevant
to the use of MAGE proteins in cancer vaccines, we have
undertaken a systematic mutational analysis of the coding regions
of the five MAGE genes in which mutations were reported
(MAGEA1, MAGEA4, MAGEC1, MAGEC2, MAGEE1). For this
study we used human melanoma and ovarian samples, two tumor
types with frequent CT-X expression. Our results reveal that one
or more of these genes is mutated in around 35% of melanomas
with some tumors exhibiting multiple mutations in these genes.
On the other hand we found no mutations of these genes in
ovarian tumors. Further investigations will be required to
determine whether these mutations are drivers or passengers of
tumorigenesis.
Materials and Methods
Sequence analysis of the melanoma samples
Tumor and matching blood samples from 27 melanoma cancer
patients were collected at Lausanne University Hospital (CHUV),
Switzerland. Cell lines were established from these samples at the
Ludwig Institute of Cancer Research, from fresh surgery samples
using mechanical or a combination of mechanical and enzymatic
dissociation. All cell lines were derived from cutaneous melano-
mas, except for T1257A and B (mucosal melanoma). They were
all from tumor metastases, except for LAU-Me300 and LAU-
T1257A, which were from primary tumors. The following pairs of
cell lines were established from the same patients: LAU-
Me260.LN and LAU-T149D (patient 149, 7 years apart); LAU-
Me275 and LAU-T50B (patient 50, 12 years apart); LAU-Me 261
and LAU-T42B (patient 42, 3 years apart); LAU-Me305 and
LAU-Me317.M2 (patient 233, 6 months apart); LAU-T1257A
and C (patient 1257, primary tumor and synchronous metastasis,
respectively); LAU-T1262 A and B (patient 1262, synchronous
metastases); LAU-T1255A/B are two independent lines from a
large tumor. Established cultures were confirmed to be from
human melanoma by flow cytometric analysis with antibodies
against the high molecular weight melanoma- associated antigen
and MHC class I molecules. Additional phenotyping was
performed by flow cytometry, Western blotting and RT/PCR to
assess expression of melanoma/melanocytic antigens (e.g. MART-
1, tyrosinase, cancer/testis genes). Cell lines were routinely tested
and found negative for mycoplasma. Cells were periodically
checked for morphology and expression of selected antigens by
RT/PCR.
In addition, fresh tumor and blood samples were collected from
86 patients attending the Melanoma Clinic at Austin Health,
Melbourne, Australia (Table S2). A written informed consent was
obtained from all participating subjects. This study was approved
by the Ethics Committee for Clinical Research from the University
of Lausanne, Switzerland, by the Human Research Ethics
Committee, Research Ethics Unit, Austin Hospital, Australia
and by the Ethics Committee, J. Craig Venter Institute.
Genomic DNA was extracted using a Qiagen kit following a
standard protocol. Targeted sequencing was carried out with a
fully automated and high-throughput production pipeline that is
based on polymerase chain reaction (PCR) amplification of
genomic DNA followed by traditional Sanger sequencing
chemistry as previously described [20]. Primer sequences are
listed in Table S3. Mutational analysis was done by comparing the
sequence traces between tumors and their matching blood
samples. Each somatic mutation call had to be supported by both
forward and reverse traces of each amplicon and was manually
verified.
Cloning of and sequencing analysis of mutated MAGEA1
in LAU-Me190
PCR was undertaken with High Fidelity Taq polymerase
(Invitrogen, Carlsbad, CA) plus 10 pmol of each of the following
primers in 25 ml to amplify the region containing the sequence
variation in the tumor corresponding to the LAU-Me190 cell line:
Forward 59-AGAAAACCAACCAAATCAGCCA-39and Reverse
59-TCATGTCTCTTGAGCAGAGGAGTCT-39. The amplifica-
tion consisted of 35 cycles of a denaturation step at 94uC for 30 s,
followed by 30 s at 55uC and extension at 68uC for 30 s followed
by a final 7-min extension. PCR products were loaded onto 1.5%
agarose gel, stained with ethidium bromide and visualized by UV
illumination. The predicted size of the MAGEA1 PCR product
was 340 bp. The PCR product was recovered and purified after
agarose gel electrophoresis using a QIAquick Gel Extraction Kit
(Qiagen, Valencia, CA). Cloning in pcDNA
TM3.1/V5-His was
performed at room temperature for 30 minutes in a total volume
of 6 ml using the pcDNA
TM3.1/V5-His TOPOH TA Expression
Kit (Invitrogen, Carlsbad, CA). Transformation was performed
into chemically competent One ShotH TOP10 E. coli (Invitrogen,
Carlsbad, CA) that were plated in LB plates containing 100 mg/ml
ampicillin and incubated overnight at 37uC. Fifteen colonies were
picked and grown overnight in LB medium containing 100 mg/ml
ampicillin. Plasmids were isolated with WizardH Plus SV
Minipreps DNA Purification System (Promega Madison, WI).
DNA was submitted to Sanger sequencing using the T7 promoter
primer.
Results and Discussion
The entirety of MAGEA1, MAGEA4 and MAGEC2 genes and at
least 70% of MAGEC1 and MAGEE1 could be specifically PCR
amplified thus permitting detection of somatic mutations by
conventional Sanger sequencing. Some regions of MAGEC1 and
MAGEE1 could not be covered by PCR amplicons due to very
high GC content or repetitive sequences.
To avoid the complication of contaminating normal tissues in
fresh tumor samples, we first undertook a Discovery Screen for
MAGE mutations using melanoma cell lines and corresponding
EBV transformed leukocytes from 27 patients treated at the
University Hospital in Lausanne, Switzerland (CHUV). We
detected a total of 15 somatic MAGE coding region mutations in
these cell lines, with at least one mutation in each of the five genes
examined (Table 1). Two other genes were also sequenced in these
samples, PRAME, on chromosome 22 and DDX53 on the X-
chromosome, and served as negative controls as no mutations
were found. As a positive control, the expected mutation
frequencies of the major cancer genes TP53 and BRAF were
found in these cell lines (Table S1).
Overall, cell lines from 10 of the 27 patients exhibited MAGE
mutations (37%). From five of the patients where MAGE
mutations were found, fresh tumor tissue was also available. In
four of these we were also able to identify the mutation found in
the cell line in the fresh tissue. The exception was the tumor
MAGE Mutations in Melanoma
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the latter). One explanation for this could be tumor heterogeneity,
which would render mutations present in small subset of cells
undetectable by the sequencing technology used. To investigate
this possibility, we selected one mutation, S33F in MAGEA1, for
further study. We amplified the mutated region from the tumor
tissue and cloned the amplification products into a plasmid and
sequenced the clones. Two of 15 clones were found to contain the
mutation. Thus for this mutation we were able to confirm the
mutation in the original tissue in a subset of alleles.
Two of the mutations detected occurred in cell lines from
patients for which additional autologous melanoma lines estab-
lished from separate metastases were available. In one case, the
lines (LAU-Me275 and LAU-T50B) were established twelve years
apart and in the second (cell lines LAU-Me261 and LAU-T42B),
the lines were established three years apart. We tested these
additional lines for the presence of the mutations. In both cases,
the mutations were found in the paired asynchronous cell lines.
Based on our finding of MAGE mutations in the melanoma cell
line samples, a Validation Screen was undertaken in which we
sequenced the same MAGE genes in 111 fresh tumor samples
collected from 86 melanoma patients who had undergone surgical
intervention at the Melanoma Clinic at Austin Health, Melbourne,
Australia (Table 2). In addition, we sequenced the same genes in
33 samples from ovarian tumors collected at Roswell Park Cancer
Center, Buffalo, New York. We identified additional somatic
coding region mutations for each of the genes in the melanoma
samples. Overall, 32% of the melanoma patients had a mutation
in at least one of the genes sequenced. The frequencies of patients
with missense or nonsense mutations for the individual genes were
5.8%, 11.6%, 15.1% and 7.0% and 7.0% for MAGEA1, MAGEA4,
MAGEC1, MAGEC2 and MAGEE1 respectively. More than one
sample was available from six of the patients. In all cases where a
MAGE mutation was found in one sample, it was also found to be
present in the other samples from the same patient. We observed
coding region mutation frequencies of 47.8% and 20.4%
respectively for BRAF and TP53 in the samples in the Validation
Screen (Table S2). These frequencies are both consistent with
those reported by others for these genes in melanoma arguing that
our findings are representative. In contrast to the melanoma
samples, no MAGE mutations were identified in any of the ovarian
samples sequenced although a mutation frequency of 31% was
found for TP53 (Table S4). This frequency is consistent with the
findings of others [21] suggesting that the samples were sufficiently
enriched for tumor derived cells to permit the detection of MAGE
mutations were they to be present. The apparent lack of mutations
in the ovarian samples studied points to a distinct tumorigenic
pathway for the ovarian tumors and melanoma where MAGE
genes may play different roles.
In addition to generating new mutation data, we also combed
the publically available databases and found a small number of
additional mutations in lung tumors, glioblastoma, breast tumors
and melanoma in MAGE genes [17,18,19,22] (Table 3). On the
other hand, some tumor types known to express CT-X genes, such
as colon, bladder and ovarian (as confirmed here), have no
recorded mutations to date.
The recent sequencing of a melanoma genome has revealed a
mutation spectrum reflective of the mutagenic impact of ultraviolet
light [23]. This pattern can be clearly observed in this study in that
C.T-G .A alterations represent almost 89% of the MAGE
mutations found (Table S5), with over 90% of these occurring at
dipyrimidine sites. This UV mutation signature pattern was also
observed for TP53 in the melanoma samples analyzed here. It was
not, however, observed in the MAGE mutations found in other
tumor types.
Overall, the non-synonymous to synonymous ratio of the MAGE
mutations was found to be 2.45:1. This is not different from the
ratio that would be expected to occur by chance. However, this
low non-synonymous:synonymous ratio is largely due to a very
high proportion of synonymous mutations in MAGEC1 and
MAGEC2 (14 of 20). MAGEA1, MAGEA4, and MAGEE1 have
non-synonymous to synonymous ratios of 6:1, 5:1 and 2.66:1
respectively. Moreover, all the mutations in the two MAGEA genes
reported in the databases are non-synonymous (Table 1). Thus,
MAGEA mutations might be drivers of tumorigenesis, as has
previously been postulated for MAGEE1. Due to their distribution
throughout the genes studied (Figure 1), we speculate that the
MAGE mutations we have identified are more likely to be
Table 1. Somatic mutations identified in MAGE genes in the discovery set.
Gene Sample name Amino acid Codon change TP53 status BRAF status
MAGEA1 LAU-Me190 S33F TCC.TTC WT V600E
MAGEA1 LAU-Me190 L129L CTG.CTA WT V600E
MAGEA4 LAU-Me190 E34K GAG.AAG WT V600E
MAGEC1 LAU-Me190 E877K GAG.AAG WT V600E
MAGEC1 LAU-Me190 F144F TTC.TTT WT V600E
MAGEC1 LAU-Me243 P756S CCC.TCC WT WT
MAGEC1 LAU-Me200 G769R GGG.AGG S241F WT
MAGEC2 LAU-Me275 S110N AGC.AAC WT V600E
MAGEC2 LAU-Me243 R271R AGG.AGA WT WT
MAGEC2 LAU-Me300 S111L TCA.TTA WT V600E
MAGEC2 LAU-Me280.R.LN P295L CCA.CTA P278S G593S; L597R
MAGEC2 LAU-Me261 S51F TCC.TTC S241F WT
MAGEE1 LAU-Me290 P324S CCT.TCT WT WT
MAGEE1 LAU-T441A P568L CCC.CTC WT WT
MAGEE1 LAU-Me281 T330T ACC.ACG WT V600E
doi:10.1371/journal.pone.0012773.t001
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Gene Sample name Amino acid Codon change TP53 status BRAF status
MAGEA1 04-007 S296P TCC.CCC WT V600E
MAGEA1 7552 L271F CTC.TTC WT V600E
MAGEA1 4198 E217K GAG.AAG R110C, Q100stop, P36L NA
MAGEA1 6227 D258A GAT.GCT FS at H179* WT
MAGEA1 6613 R236K AGG.AAG R181P WT
MAGEA4 6541 G316R GGA.AGA WT V600E
MAGEA4 7889 S99L TCG.TTG R282P WT
MAGEA4 4198 E138K GAG.AAG R110C, Q100stop, P36L NA
MAGEA4 4198 P149S CCT.TCT R110C, Q100stop, P36L NA
MAGEA4 6985 E224K GAG.AAG WT WT
MAGEA4 02-105 P267S CCT.TCT WT WT
MAGEA4 7194 E242K GAG.AAG R196stop WT
MAGEA4 03-043 R269C CGC.TGC WT WT
MAGEA4 5668 I222I ATC.ATT WT WT
MAGEA4 2112 E21E GAG.GAA WT V600E
MAGEA4 5558 P45S CCT.TCT S241F WT
MAGEC1 07-223 F904F TTC.TTT WT V600E
MAGEC1 04-007 P26L CCT.CTT WT V600E
MAGEC1 04-007 L35F CTC.TTC WT V600E
MAGEC1 7889 E991K GAG.AAG R282P WT
MAGEC1 4198 E59E GAG.GAA R110C, Q100stop, P36L NA
MAGEC1 4198 D62N GAC.AAC R110C, Q100stop, P36L NA
MAGEC1 4198 P38S CCC.TCC R110C, Q100stop, P36L NA
MAGEC1 6985 P83S CCC.TCC WT WT
MAGEC1 6985 S688F TCC.TTC WT WT
MAGEC1 6985 S863L TCA.TTA WT WT
MAGEC1 6458 K1104K AAG.AAA R248W WT
MAGEC1 7151 P119S CCT.TCT WT V600E
MAGEC1 7194 Q664stop CAG.TAG R196stop WT
MAGEC1 7194 E668E GAG.GAA R196stop WT
MAGEC1 7194 P127L CCT.CTT R196stop WT
MAGEC1 4066 F904F TTC.TTT WT V600E
MAGEC1 02-024 L705L CTG.TTG R213stop WT
MAGEC1 6795 G986E GGG.GAG WT WT
MAGEC1 4985 S964S TCC.TCA WT WT
MAGEC1 4985 S18S TCC.TCT WT WT
MAGEC1 4985 D687N GAT.AAT WT WT
MAGEC1 4062 P50S CCT.TCT WT V600K
MAGEC1 03-063 S134S TCC.TCT WT G596R
MAGEC2 07-223 P3S CCC.TCC WT V600E
MAGEC2 4198 F151Y TTC.TAC R110C, Q100stop, P36L NA
MAGEC2 4198 E36E GAG.GAA R110C, Q100stop, P36L NA
MAGEC2 6985 S58F TCC.TTC WT WT
MAGEC2 7516 F265F TTC.TTT R337S WT
MAGEC2 7259 D335N GAT.AAT WT WT
MAGEC2 02-102 P84P CCC.CCT WT V600E
MAGEE1 6541 D446C GAT.TGT* WT V600E
MAGEE1 4198 R711K AGG.AAG R110C, Q100stop, P36L NA
MAGEE1 6985 S319S TCC.TCT WT WT
MAGEE1 03-091 A717V GCT.GTT WT G469E
MAGE Mutations in Melanoma
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genes where the NS:S ratio is suggestive of their being drivers,
there is evidence that both play tumor suppressive roles. MAGEA1
expression was shown to correlate with good prognosis in
neuroblastoma [14] and MAGEA4 expression was shown to
promote tumor cell death and sensitize lung malignancies to
apoptotic stimuli, such as chemotherapeutic agents [16]. MA-
GEA4 was also shown to interact with gankyrin and to suppress its
oncogenic activity [24]. It is thus possible, that the inactivation of
MAGEA1 and MAGEA4, which are generally expressed in
coordination with other CT-X genes such as MAGEA2 and
MAGEA3 for which there is evidence for oncogenic function,
might enhance the overall tumorigenicity of coordinated CT-X
expression leading to a net positive contribution to tumor
progression.
Recently the X-ray structure of the MAGE homology domain
of MAGEA4 (PDB ID 2WA0) was determined. This permitted a
more detailed analysis of the mutations that fall within this domain
in the various family members, as described in Supplementary
Methods S1. We found that the mutations found in this region
involve residues that have a higher solvent exposure and a lower
FoldX score [25] than average, implying that they do not play an
important role in the structural integrity of the protein but might
serve for interactions with other molecules (Supplementary
Methods S1 and Table S6). Although it is unclear whether the
MAGE homology domain is involved in binding interactions, this
observation reinforces the possibility of the mutations resulting in
discrete functional changes.
One other aspect of the MAGE gene mutations worthy of
further investigation is their frequent occurrence in potential
phosphorylation sites. As predicted by http://scansite.mit.edu/,
these mutations could either abolish predicted existing sites or
create new potential sites (A63P [new site at S62], K278T and
S296P in MAGEA1; P45S, S99L, P149S and P267S in MAGEA4;
P38S, P83S and S86L in MAGEC1; S51F, S58F, S110N, S111L,
F151Y and P295L [new sites at S293, Y296 and Y297] in
Table 3. Somatic mutations identified in MAGE genes in genome wide surveys.
Gene Sample name (tumor type) Amino acid Codon change TP53 status BRAF status Reference
MAGEA1 HCC1008 (breast cancer cell line) K278T AAA.ACA D281H WT [17]
MAGEA1 NCI-H1770 (NSCLC cell line) A63P GCC.CCC R248W WT [22]
MAGEA4 HCC1008 (breast cancer cell line) G153D GGC.GAC D281H WT [17]
MAGEA4 Br27P (glioma) E221K GAA.AAA c.617delT (fs) T310I [18]
MAGEB6B NCI-H2087 (NSCLC cell line) G71.F GGT.TTT V157F L597V [22]
MAGEB10 Br09PT (glioma) D55Y GAT.TAT W53X WT [18]
MAGEB10 LB647-SCLC (SCLC cell line) Q148K CAG.AAG p.E294fs*51 WT [22]
MAGEB16 NCI-H2009 (NSCLC cell line) T302R ACA.AGA R273L WT [22]
MAGEB16 LB647-SCLC (SCLC cell line) A279T GCT.ACT p.E294fs*51 WT [22]
MAGEB16 HCC2218 (breast cancer cell line) L323L CTG.CTT R283C WT [17]
MAGEC1 Br02X (glioma) I1001F ATT.TTT WT WT [18]
MAGEC2 HCC1954 (breast cancer cell line) G6C GGC.TGC Y163C WT [17]
MAGEC3 MZ7-mel (melanoma cell line) D50N GAC.AAC WT V600E [22]
MAGEC3 CP66-MEL (melanoma cell line) L551F CTT.TTT WT WT [22]
MAGED2 Hs 578T (breast cancer cell line) K458Q AAG.CAG V157F WT [22]
MAGEE1 HCC2713 (breast cancer cell line) Y640F TAC.TTC c.723delC (fs) NA [22]
MAGEE1 CP66-MEL (melanoma cell line) R934K AGG.AAG WT WT [22]
MAGEE1 HCC1008 (breast cancer cell line) T664N ACC.AAC D281H WT [17]
MAGEE1 Pa14C (pancreas tumor) V649V GTG.GTT WT WT [19]
MAGEH1 Br23X (glioma) A13A GCG.GCA WT WT [18]
MAGEH1 NCI-H2087 (NSCLC cell line) F100F TTC.TTT V157F L597V [22]
*Two consecutive changes.
doi:10.1371/journal.pone.0012773.t003
Gene Sample name Amino acid Codon change TP53 status BRAF status
MAGEE1 08-249E A859A GCC.GCT WT V600K
MAGEE1 8022 S67F TCC.TTC WT V600E
MAGEE1 4985 E692D GAA.GAT WT WT
MAGEE1 4985 E693K GAA.AAA WT WT
doi:10.1371/journal.pone.0012773.t002
Table 2. Cont.
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the MAGE proteins are phosphorylated, this observation does hint
at potential functional consequence of many of the mutations.
Lastly, we considered the possibility that selective immune
pressure that might underlie the MAGE mutations. In this context,
six of the eight missense mutations identified in MAGEA1 (residues
63, 236, 258, 271, 278, 296), the only one of the genes sequenced
where extensive mapping of T cell epitopes has been performed,
affect known epitopes [26]. Thus, the mutations might reduce
antigenicity and serve as an alternate escape mechanism to loss of
antigen or MHC expression. It remains to be determined,
however, whether the mutated epitopes were involved in
antigenicity in the patients where they were identified.
An o t a b l ef a c e to ft h eMAGE mutations is their non-random
distribution between patients. Thirty five of the fifty four MAGE
mutations (64.8%) in our Validation and Discovery Screens are from
samples that exhibit more than one mutation, often with multiple
mutations in the same gene. For example, one sample in the
Validation Screen, 4198, exhibited nine coding region mutations and
another, 6985, six mutations. Even in the list of mutations identified
in other studies, 41% are from samples where more than one MAGE
mutation has been identified. These data suggest that a significant
subset of the mutations might arise due to a DNA instability
syndrome, either affecting the X-chromosome or the entire genome.
While our results do not as yet define the functional con-
sequences of the MAGE gene mutations observed, they do
demonstrate for the first time that this gene family is frequently
mutated in melanoma. Therefore, our study argues for enhanced
efforts to discern potential tumorigenic properties of these genes
that serve as the platform for therapeutic cancer vaccines already
in advanced clinical development.
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